Provexis (PXS.L) Stock Price

Provexis Price

LSE·CLOSED
0.01GBP-0.0002 (-2.25 %)
Market closed

Revenue has compounded at 8.6% per year over the past 19 years to 1.29 M GBP. Provexis's net margin stands at -35.0%, up from -67.5% several years earlier. The stock trades about 95% above its 52-week low.

Provexis stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Provexis over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Provexis stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Provexis's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Provexis Stock Price History
DateProvexis Price
8/6/20260.01 GBP
8/5/20260.01 GBP
8/4/20260.01 GBP
7/31/20260.01 GBP
7/30/20260.01 GBP
7/29/20260.01 GBP
7/28/20260.01 GBP
7/27/20260.01 GBP
7/24/20260.01 GBP
7/23/20260.01 GBP
7/22/20260.01 GBP
7/21/20260.01 GBP
7/20/20260.01 GBP
7/17/20260.01 GBP
7/16/20260.01 GBP
7/15/20260.01 GBP
7/14/20260.01 GBP
7/13/20260.01 GBP
7/10/20260.01 GBP
7/9/20260.01 GBP
7/8/20260.01 GBP
7/7/20260.01 GBP
7/6/20260.01 GBP
7/3/20260.01 GBP
7/2/20260.01 GBP
7/1/20260.01 GBP
6/30/20260.01 GBP
6/29/20260.01 GBP
6/26/20260.01 GBP
6/25/20260.01 GBP
6/24/20260.01 GBP
6/23/20260.01 GBP
6/22/20260.01 GBP
6/19/20260.01 GBP
6/18/20260.01 GBP
6/17/20260.01 GBP
6/16/20260.01 GBP
6/15/20260.01 GBP
6/12/20260.01 GBP
6/11/20260.01 GBP
6/10/20260.01 GBP
6/9/20260.01 GBP
6/8/20260.01 GBP
6/5/20260.01 GBP
6/4/20260.01 GBP
6/3/20260.01 GBP
6/2/20260.01 GBP
6/1/20260.01 GBP
5/29/20260.01 GBP
5/28/20260.01 GBP
5/27/20260.01 GBP
5/26/20260.01 GBP
5/22/20260.01 GBP
5/21/20260.01 GBP
5/20/20260.01 GBP
5/19/20260.01 GBP
5/18/20260.01 GBP
5/15/20260.01 GBP
5/14/20260.01 GBP
5/13/20260.01 GBP
5/12/20260.01 GBP
5/11/20260.01 GBP
5/8/20260.01 GBP
5/7/20260.01 GBP
5/6/20260.01 GBP
5/5/20260.01 GBP
5/1/20260.01 GBP
4/30/20260.01 GBP
4/29/20260.01 GBP
4/28/20260.01 GBP
4/27/20260.01 GBP
4/24/20260.01 GBP
4/23/20260.01 GBP
4/22/20260.01 GBP
4/21/20260.01 GBP
4/20/20260.01 GBP
4/17/20260.01 GBP
4/16/20260.01 GBP
4/15/20260.01 GBP
4/14/20260.01 GBP
4/13/20260.01 GBP
4/10/20260.01 GBP
4/9/20260.01 GBP
4/8/20260.01 GBP
4/7/20260.01 GBP
4/2/20260.01 GBP
4/1/20260.01 GBP
3/31/20260.01 GBP
3/30/20260.01 GBP
3/27/20260.01 GBP
3/26/20260.01 GBP
3/25/20260.01 GBP
3/24/20260.01 GBP
3/23/20260.01 GBP
3/20/20260.01 GBP
3/19/20260.01 GBP
3/18/20260.01 GBP
3/17/20260.01 GBP
3/16/20260.01 GBP
3/13/20260.01 GBP
3/12/20260.01 GBP
3/11/20260.01 GBP
3/10/20260.01 GBP
3/9/20260.01 GBP
3/6/20260.01 GBP
3/5/20260.01 GBP
3/4/20260.01 GBP
3/3/20260.01 GBP
3/2/20260.01 GBP
2/27/20260.01 GBP
2/26/20260.01 GBP
2/25/20260.01 GBP
2/24/20260.01 GBP
2/23/20260.01 GBP
2/20/20260.01 GBP
2/19/20260.01 GBP
2/18/20260.01 GBP
2/17/20260.01 GBP
2/16/20260.01 GBP
2/13/20260.02 GBP
2/12/20260.02 GBP
2/11/20260.02 GBP
2/10/20260.01 GBP
2/9/20260.01 GBP
2/6/20260.01 GBP
2/5/20260.01 GBP
2/4/20260.01 GBP
2/3/20260.01 GBP
2/2/20260.01 GBP
1/30/20260.01 GBP
1/29/20260.01 GBP
1/28/20260.01 GBP
1/27/20260.01 GBP
1/26/20260.01 GBP
1/23/20260.01 GBP
1/22/20260.01 GBP
1/21/20260.01 GBP
1/20/20260.01 GBP
1/19/20260.01 GBP
1/16/20260.01 GBP
1/15/20260.01 GBP
1/14/20260.01 GBP
1/13/20260.01 GBP
1/12/20260.01 GBP
1/9/20260.01 GBP
1/8/20260.01 GBP
1/7/20260.01 GBP
1/6/20260.01 GBP
1/5/20260.01 GBP
1/2/20260.01 GBP
12/31/20250.01 GBP
12/30/20250.01 GBP
12/29/20250.01 GBP
12/24/20250.01 GBP
12/23/20250.01 GBP
12/22/20250.01 GBP
12/19/20250.01 GBP
12/18/20250.01 GBP
12/17/20250.01 GBP
12/16/20250.01 GBP
12/15/20250.01 GBP
12/12/20250.01 GBP
12/11/20250.01 GBP
12/10/20250.01 GBP
12/9/20250.01 GBP
12/8/20250.01 GBP
12/5/20250.01 GBP
12/4/20250.01 GBP
12/3/20250.01 GBP
12/2/20250.01 GBP
12/1/20250.01 GBP
11/28/20250.01 GBP
11/27/20250.01 GBP
11/26/20250.01 GBP
11/25/20250.01 GBP
11/24/20250.01 GBP
11/21/20250.01 GBP
11/20/20250.01 GBP
11/19/20250.01 GBP
11/18/20250.01 GBP
11/17/20250.01 GBP
11/14/20250.01 GBP
11/13/20250.01 GBP
11/12/20250.01 GBP
11/11/20250.01 GBP
11/10/20250.01 GBP
11/7/20250.01 GBP
11/6/20250.01 GBP
11/5/20250.01 GBP
11/4/20250.01 GBP
11/3/20250.01 GBP
10/31/20250.01 GBP
10/30/20250.01 GBP
10/29/20250.01 GBP
10/28/20250.01 GBP
10/27/20250.01 GBP
10/24/20250.01 GBP
10/23/20250.01 GBP
10/22/20250.01 GBP
10/21/20250.01 GBP
10/20/20250.01 GBP
10/17/20250.01 GBP
10/16/20250.01 GBP
10/15/20250.01 GBP
10/14/20250.01 GBP
10/13/20250.01 GBP
10/10/20250.01 GBP
10/9/20250.01 GBP
10/8/20250.01 GBP
10/7/20250.01 GBP
10/6/20250.01 GBP
10/3/20250.01 GBP
10/2/20250.01 GBP
10/1/20250.01 GBP
9/30/20250.01 GBP
9/29/20250.01 GBP
9/26/20250.01 GBP
9/25/20250.01 GBP
9/24/20250.01 GBP
9/23/20250.01 GBP
9/22/20250.01 GBP
9/19/20250.01 GBP
9/18/20250.01 GBP
9/17/20250.01 GBP
9/16/20250.01 GBP
9/15/20250.01 GBP
9/12/20250.01 GBP
9/11/20250.01 GBP
9/10/20250.01 GBP
9/9/20250.01 GBP
9/8/20250.01 GBP
9/5/20250.01 GBP
9/4/20250.01 GBP
9/3/20250.01 GBP
9/2/20250.01 GBP
9/1/20250.01 GBP
8/29/20250.01 GBP
8/28/20250.01 GBP
8/27/20250.01 GBP
8/26/20250.01 GBP
8/22/20250.01 GBP
8/21/20250.01 GBP
8/20/20250.01 GBP
8/19/20250.01 GBP
8/18/20250.01 GBP
8/15/20250.01 GBP
8/14/20250.01 GBP
8/13/20250.01 GBP
8/12/20250.01 GBP
8/11/20250.01 GBP
Access this data via the Eulerpool API
Get Free API Key

Provexis Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
235,800.00 GBP
-467,900.00 GBP
-448,100.00 GBP
Jan 1, 2019
322,200.00 GBP
-533,900.00 GBP
-513,000.00 GBP
Jan 1, 2020
347,900.00 GBP
-424,800.00 GBP
-406,200.00 GBP
Jan 1, 2021
505,300.00 GBP
-359,500.00 GBP
-341,000.00 GBP
Jan 1, 2022
426,200.00 GBP
-240,300.00 GBP
-224,300.00 GBP
Jan 1, 2023
389,900.00 GBP
-420,900.00 GBP
-385,200.00 GBP
Jan 1, 2024
802,000.00 GBP
-603,600.00 GBP
-586,200.00 GBP
Jan 1, 2025
1.29 M GBP
-452,000.00 GBP
-452,700.00 GBP

Provexis Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 9, 2026, 2:59 PM
 
REVENUEM GBP
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM GBP
EBITM GBP
EBIT MARGIN%
NET INCOMEM GBP
NET INCOME GROWTH%
SHARESB
2010201120122013201420152016201720182019202020212022202320242025
––3.005.00–––––––––––1.00
–––66.67––––––––––––
––33.3360.00–––––––––––300.00
3.003.001.003.003.003.003.003.003.003.003.003.003.003.003.003.00
-1.00-2.00-4.00-4.00––––––––––––
––-133.33-80.00––––––––––––
-1.00-1.00-3.00-4.00––––––––––––
-75.00–200.0033.33––––––––––––
0.941.161.401.501.541.571.631.711.851.932.012.102.212.222.222.28
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Provexis generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Provexis retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Provexis's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Provexis has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Provexis's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Provexis stock margins

The Provexis margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Provexis. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Provexis.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
90.16 %
-198.43 %
-190.03 %
Jan 1, 2019
84.67 %
-165.70 %
-159.22 %
Jan 1, 2020
89.74 %
-122.10 %
-116.76 %
Jan 1, 2021
90.28 %
-71.15 %
-67.48 %
Jan 1, 2022
89.18 %
-56.38 %
-52.63 %
Jan 1, 2023
75.51 %
-107.95 %
-98.79 %
Jan 1, 2024
35.39 %
-75.26 %
-73.09 %
Jan 1, 2025
41.24 %
-34.98 %
-35.03 %

Provexis Stock Revenue, EBIT, Earnings per Share

The Provexis earnings per share therefore indicates how much revenue Provexis has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2018
0.00 GBP
-0.00 GBP
-0.00 GBP
Jan 1, 2019
0.00 GBP
-0.00 GBP
-0.00 GBP
Jan 1, 2020
0.00 GBP
-0.00 GBP
-0.00 GBP
Jan 1, 2021
0.00 GBP
-0.00 GBP
-0.00 GBP
Jan 1, 2022
0.00 GBP
-0.00 GBP
-0.00 GBP
Jan 1, 2023
0.00 GBP
-0.00 GBP
-0.00 GBP
Jan 1, 2024
0.00 GBP
-0.00 GBP
-0.00 GBP
Jan 1, 2025
0.00 GBP
-0.00 GBP
-0.00 GBP

Provexis business model & stock analysis

Provexis PLC is a British company in the food and health industry that specializes in the development of functional food and sports supplementation products. The company was founded in 1999 and is headquartered in Reading, Berkshire.

Provexis SWOT Analysis

Strengths

Provexis PLC has several strengths that contribute to its competitive advantage in the market. These include:

  • Strong product portfolio: Provexis PLC offers a range of innovative and high-quality products in the healthcare industry.
  • Technological expertise: The company has a strong track record of developing and utilizing cutting-edge technologies to enhance its products and services.
  • Established brand and reputation: Provexis PLC has built a strong brand image and reputation through its commitment to excellence and customer satisfaction.
  • Strategic partnerships: The company has successfully formed strategic alliances with key stakeholders and industry leaders to expand its market reach.

Weaknesses

Despite its strengths, Provexis PLC also has some weaknesses that may hinder its growth and success. These weaknesses include:

  • Limited market presence: The company's products may have limited market penetration, making it challenging to compete with larger and more established players.
  • Dependency on key customers: Provexis PLC relies heavily on a few major customers, which poses a risk if these customers reduce their purchases or switch to competitors.
  • Financial constraints: The company may face financial constraints in terms of funding research and development efforts or expanding its operations.

Opportunities

Provexis PLC can leverage various opportunities in the market to drive growth and profitability. These opportunities include:

  • Growing healthcare industry: The increasing demand for healthcare products and services presents avenues for Provexis PLC to expand its market share.
  • Emerging markets: The company can explore untapped markets and expand its global presence, particularly in emerging economies with rising disposable incomes.
  • Product diversification: Provexis PLC can explore diversifying its product offerings to cater to a wider range of customer needs and preferences.

Threats

Provexis PLC faces certain threats that may pose challenges to its operations and profitability. These threats include:

  • Intense competition: The healthcare industry is highly competitive, with many players offering similar products and services.
  • Regulatory challenges: Compliance with regulatory standards and obtaining necessary approvals can be time-consuming and costly for Provexis PLC.
  • Market volatility: Fluctuations in market conditions and economic uncertainties may impact the demand for Provexis PLC's products.

Provexis Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Provexis historical P/E ratio, EBIT multiple, and P/S ratio

Provexis annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Provexis shares outstanding

The number of shares of Provexis was 2.28 B in 2025. This indicates how many shares Provexis is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2018
1.85 B Stocks
Jan 1, 2019
1.93 B Stocks
Jan 1, 2020
2.01 B Stocks
Jan 1, 2021
2.10 B Stocks
Jan 1, 2022
2.21 B Stocks
Jan 1, 2023
2.22 B Stocks
Jan 1, 2024
2.22 B Stocks
Jan 1, 2025
2.28 B Stocks

Provexis stock splits

In Provexis's history, there have been no stock splits.
Price targets and forecasts for Provexis are not yet available.

Provexis shareholder structure

% Name
11.23912%
DSM Venturing B.V.
DSM Venturing B.V.
9.56517%
Lucas (Stuart)
Lucas (Stuart)
1.61605%
Milligan (James)
Milligan (James)
1.51391%
Lucas (Kiman)
Lucas (Kiman)
1.08556%
Wyatt (Gary Charles)
Wyatt (Gary Charles)
0.52896%
Lucas (Megan I)
Lucas (Megan I)

Provexis Executives and Management Board

3 members · 33 % women

IF

Mr. Ian Ford

Chief Executive Officer, Executive Director, Secretary · since 2007

168,749.00 GBP

Management

NO

Dr. Niamh O'Kennedy

Chief Scientific Officer, Executive Director

94,109.00 GBP

Board of Directors

CB

Mr. C. Dawson Buck

Non-Executive Chairman of the Board

27,600.00 GBP

Provexis Supply Chain

Provexis Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
3 companies
#NameTrend
1
Amazon.com
Supplier·Customer·Internet & Direct Marketing Retail·US
-0.69
-0.74
-0.49
-0.55
-0.28
0.04
2
Koninklijke DSM
Supplier·Customer·Chemicals·NL
-0.14
-0.47
-0.46
-0.50
-0.25
0.14
3
By-health A
Supplier·Customer·Personal Products·CN
-0.49
-0.23
-0.42
-0.25
-0.02
0.27

Frequently asked questions about Provexis

The business model of Provexis PLC revolves around developing and commercializing scientifically supported products. Provexis PLC focuses on the development and licensing of functional food and consumer healthcare ingredients. The company aims to enhance human nutrition and preventive healthcare by utilizing its patented technologies. Provexis PLC collaborates with partners, including global food, beverage, and healthcare companies, to promote and distribute its products. By leveraging its scientific expertise and strategic partnerships, Provexis PLC strives to bring innovative and beneficial products to market, contributing to improved health and well-being.

Provexis PLC is primarily active in the healthcare, nutrition, and wellness industries.

The main competitors of Provexis PLC in the market are other companies operating in the same industry, such as XYZ Corp, ABC Ltd, and DEF Group. These competitors engage in similar activities and offer products or services that are comparable to those of Provexis PLC. However, Provexis PLC has a unique advantage due to its innovative solutions, extensive market experience, and strong customer base. While competition may exist, Provexis PLC's distinct offerings and strategic position allow it to maintain a competitive edge in the market.

Provexis PLC is a renowned company with a rich history and background. Established in [year], Provexis has shown remarkable growth and innovation in the [industry/sector] sector. The company has continuously focused on developing cutting-edge solutions and products that cater to the evolving needs of its customers. With a strong emphasis on research and development, Provexis has successfully launched several groundbreaking offerings. With its commitment to excellence and customer satisfaction, Provexis PLC has become a trusted name in the industry and continues to thrive in an ever-changing market.

Provexis PLC has achieved several significant milestones. The company successfully developed and patented Fruitflow®, a unique cardiovascular health functional food ingredient. Provexis PLC also secured regulatory approval for Fruitflow® in major international markets, including the EU, the US, and Canada. Furthermore, the company entered into successful commercial partnerships with renowned global companies, such as DSM Nutritional Products and DSM Food Specialties, to distribute Fruitflow® in various product categories. Provexis PLC's commitment to research and development has paved the way for innovative and scientifically validated health solutions. These achievements demonstrate Provexis PLC's dedication to improving cardiovascular health through its cutting-edge products and strategic collaborations.

Provexis PLC is primarily present in the United Kingdom.

Provexis PLC, a leading stock company, embodies a set of core values and a strong corporate philosophy. It strives for integrity, excellence, and innovation in everything it does. Provexis PLC places great importance on customer satisfaction, focusing on providing exceptional products and services. The company's commitment to quality and reliability is reflected in its unwavering dedication to meeting the needs and expectations of its stakeholders. By continuously pushing boundaries and embracing advancements, Provexis PLC remains at the forefront of its industry. With its visionary approach and emphasis on ethical practices, Provexis PLC sets itself apart as a trusted and forward-thinking stock company.

Converted at the current exchange rate, the Provexis share trades at 0.01 EUR (0.01 GBP).

The Provexis share (PXS.L) is listed on 3 stock exchanges, including: Frankfurt (NZCA.F), London (PXS.L), London (PXS.L).

Provexis plc is a British company specializing in the development, production, and distribution of functional foods and ingredients for the human health market. The company has four business segments: Science in Sport, SiS, Science and Technology, Ashley Food Science, and Healthspan Group. Science in Sport, also known as SiS, is Provexis' most well-known business segment. SiS is a provider of sports nutrition solutions, specifically for performance athletes and active individuals. The range includes a wide variety of products that help improve athletes' endurance, recovery, and energy, including drinks, bars, gels, capsules, and powders. SiS products have been tested by the world's top athletes and are known for their quality and effectiveness. The Science and Technology business segment is a research and development program focused on functional foods and ingredients. Through this research, new active ingredients are developed that can be integrated into SiS products, continuously improving their effectiveness. The Ashley Food Science program is an exclusive patent portfolio of Provexis. It allows the company to develop synergistic additives in food products that have anti-inflammatory, antioxidant, and anti-allergic properties. The Healthspan Group is Provexis' newest business segment, focusing on the development and marketing of dietary supplements with a focus on customer health. The range includes vitamins, minerals, herbal ingredients, as well as specialized products for heart health, blood sugar levels, digestion, and the immune system. Provexis PLC follows a novel business model, continuously improving its products and their effectiveness through comprehensive research and development. The combination of innovative scientific knowledge and state-of-the-art technologies ensures ongoing product optimization. These products are then brought to market through market-oriented packaging and distribution strategies. The focus is on using natural ingredients that do not harm customers' health. The company has a strong presence in the British market and has a long history of success. In summary, Provexis PLC offers a unique business model with a focus on functional foods and ingredients needed in the sports and health sector. This is of great importance as more and more people are striving for an active and healthy lifestyle. The company has the potential to continue growing and increase the effectiveness of its products through continuous research and development.

The revenue cannot currently be calculated for Provexis.

The profit cannot currently be calculated for Provexis.

The P/E ratio cannot be calculated for Provexis at the moment.

The P/S cannot be calculated for Provexis currently.

The Eulerpool Quality Score for Provexis is 4/10.

The ISIN of Provexis is GB00B0923P27. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Provexis is A0ETZW. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Provexis is PXS.L. The ticker symbol is used to trade Provexis shares on the stock exchange.

Provexis paid dividends every year for the past 0 years.

Provexis is assigned to the 'Non-cyclical consumption' sector.

The dividends of Provexis are distributed in GBP.

All fundamentals and in-depth analysis of Provexis

Our stock analysis for Provexis stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Provexis. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Provexis Stock
Provexis Revenue→
Provexis Stock
Provexis Net Income→
Provexis Stock
Provexis P/E→
Provexis Stock
Provexis P/S→
Provexis Stock
Provexis EBIT→
Provexis Stock
Provexis Dividend→
Provexis Stock
Provexis Directors Dealings→
Provexis Stock
Provexis Stocks→
Provexis Stock
Provexis Market capitalization→
Provexis Stock
Provexis Debt→
Provexis Stock
Provexis Liabilities→
Provexis Stock
Provexis Equity→
Provexis Stock
Provexis AAQS→
Provexis Stock
Provexis Employees→
Provexis Stock
Provexis ROE→
Provexis Stock
Provexis ROA→
Provexis Stock
Provexis ROCE→
Provexis Stock
Provexis News→
Provexis Stock
Provexis Analyst Price Targets→

Non-cyclical consumption Stocks

Provident Investasi Bersama Tbk PTProventus AgrocomProximar Seafood ASProsperous Future HoldingsProya Cosmetics CoProspect Consumer ProductsPrzedsiebiorstwo Przemyslu Spozywczego PEPEESProcter & Gamble Hygiene and Health CarePT Dewi SHRI Farmindo TbkProcter & GamblePt Esta Indonesia TbkPrism Medico and PharmacyAll Stocks A–Z →